Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)
Open Posted
- Opportunity number
- RFA-MH-27-125
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- For Profit Organizations
- Higher Education Inst. (Private)
- Small Businesses
- Non-501(c)(3) Nonprofits
- City/Township Governments
- Other
- County Governments
- State Governments
- Tribal Governments (Federally Recognized)
- Special District Governments
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- Higher Education Inst. (Public)
- Independent School Districts
- Public or Indian Housing Auth.
- Points of contact
-
- Vasudev R Rao vasudev.rao@nih.gov (301) 825-3259
- nimh.dar.inquiries@nih.gov
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute of Mental Health, in collaboration with the National Institute on Drug Abuse and National Institute of Neurological Disorders and Stroke, is forecasting a Notice of Funding Opportunity to solicit applications for research identifying modifiable mechanisms and therapeutic targets to address central nervous system complications in people with HIV, with an application deadline of October 28, 2027. This R21/R33 phased innovation award does not allow clinical trials.
Eligible applicants include higher education institutions (public and private), nonprofits (501(c)(3) and non-501(c)(3)), for-profit organizations, state and local governments, tribal governments and tribal organizations, and special district governments. Foreign organizations and non-domestic components of U.S. organizations are ineligible; foreign components are not allowed.
The three institutes intend to commit a combined $4.5 million across fiscal years 2027 and 2028 to fund 3–5 awards. The R21 Innovation Phase supports up to two years with direct costs not exceeding $275,000 total ($200,000 maximum per year). The R33 Confirmatory Phase provides up to three additional years with direct costs up to $650,000 per year. NIMH will provide $2.5 million for 2–3 awards, NINDS will provide $1 million for 1 award, and NIDA will provide $1 million for 1–2 awards.
The research approach is phased: the R21 focuses on patient-informed phenotype identification, mechanistic hypothesis generation, and platform development using patient-derived organoids and primary cell cultures; the R33 validates mechanisms across complementary models and establishes translational readiness. Applicants must submit a Data Management and Sharing Plan and Resource Sharing Plan, collect Common Data Elements, and submit data to the NIMH Data Archive. Evaluation criteria include significance, innovation, rigor, feasibility, expertise, and available resources. The Assistance Listing number is 93.242 (Mental Health Research Grants).
Synopsis
The purpose of this notice of funding opportunity (NOFO) is to identify modifiable mechanisms and therapeutic targets to address central nervous system (CNS) complications associated with human immunodeficiency virus (HIV). The initiative supports a phased research approach beginning with the identification of patient phenotypes characterized by convergent pathophysiological features, followed by the discovery and experimental validation of molecular mechanisms using innovative in-vitro and in-vivo models. The goal of this NOFO is to advance therapeutic target, and intervention discovery to address the multifactorial and heterogeneous nature of HIV-associated CNS dysfunction.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00294284.pdf | ||
| RFA-MH-27-125-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity